Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

UNI-BIO SCIENCE GROUP LIMITED
聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0690)

VOLUNTARY ANNOUNCEMENT

A STRATEGIC COOPERATION AGREEMENT ENTERED INTO BETWEEN THE GROUP, THE WMU NERC AND WENZHOU OUHAI DISTRICT PEOPLE'S GOVERNMENT

On 30 December 2025, the board of directors (the "**Board**") of Uni-Bio Science Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Group has officially signed a tripartite strategic cooperation agreement (the "**Agreement**") in Wenzhou, Zhejiang province with **the National Engineering Research Center for Cell Growth Factor Drugs and Protein Formulations of Wenzhou Medical University (the "WMU NERC")** and **Wenzhou Ouhai District People's Government**. The parties also explored the subsequent co-establishment of a "Uni-Bio-WMU Joint Innovation Laboratory for Translational Medicine (聯康-溫醫大轉化醫學聯合創新實驗室)" (the "**Joint Laboratory**"). The cooperation is expected to strengthen the Group's R&D pipeline in dermatology, ophthalmology and metabolic diseases, and accelerate the implementation of its strategy.

Pursuant to the Agreement, the three parties will leverage their respective advantages in scientific research, industry and policy to collaborate across the entire chain-from basic research and clinical translation to industrial commercialization-focusing on the application of growth-factor based drugs in regenerative medicine. The three parties intend to conduct in-depth exploration of the synergistic mechanisms of Epidermal Growth Factor (EGF) and Fibroblast Growth Factor (FGF) in areas such as regulating metabolic homeostasis, improving insulin sensitivity, and promoting tissue repair. They aims to develop novel compound formulations and drug delivery systems targeting conditions such as endocrine diseases represented by non-alcoholic steatohepatitis (NASH), respiratory diseases represented by asthma, as well as bone tissue repair. These diseases affect a large global patient population, yet there remains a significant unmet clinical need for innovative

* *For identification purpose only*

therapies. Through this collaboration and the future establishment of the Joint Laboratory, we expect to address treatment gaps in multiple specific indications, thereby further unlocking clinical and commercial value in the broad chronic disease market.

The WMU NERC is an independent legal entity established by Wenzhou Medical University (the "**WMU**"), based on the platform of the "**National Engineering Research Center for Cell Growth Factor Drugs and Protein Formulations**". Under the leadership of Chinese Academy of Engineering Academician Li Xiaokun, the center has long been dedicated to foundational research and novel drug development for cell growth factor drugs and holds a globally leading position in the field. Wenzhou Ouhai District People's Government is a key facilitator and supporter of this strategic cooperation, who is committed to building a first-class biomedical industry ecosystem. Its core platform, the "China Gene Valley (中國基因藥谷)" will provide comprehensive spatial support and specialized policy assistance for the cooperative projects across all stages-from R&D and pilot-scale testing to industrialization.

This cooperation is anticipated to enhance the Group's R&D efficiency and success rate for innovative biologics, shorten product development cycles, and strengthen its comprehensive competitiveness in the EGF/FGF segment. It will also facilitate the exploration of broader clinical applications for the Group's existing products, including GeneTime® and GeneSoft®.

The Board believes this cooperation is a key initiative for deepening the Group's "government-university-enterprise" collaboration and integrating into a national-level innovation platform. It is expected to significantly accelerate the R&D and commercialization of cutting-edge innovative pipelines, further consolidating the Group's long-term competitiveness in regenerative medicine and delivering sustained value to shareholders.

On behalf of the Board
Uni-Bio Science Group Limited
Kingsley Leung
Chairman

Hong Kong, 30 December 2025

As at the date of this announcement, the Board comprises four executive Directors, namely, Mr. Kingsley Leung (Chairman), Mr. Chen Dawei (Vice-Chairman), Mr. Zhao Zhi Gang (Chief executive) and Dr. Wen Yalei (Chief Operating Officer); two non-executive Directors, Mr. Yau Kwok Wing Tony and Ms. Zhang Qing; and three independent non-executive Directors, namely, Mr. Chow Kai Ming, Mr. Ren Qimin and Mr. Ma Qingshan.